Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective
Due to the high prostate cancer incidence worldwide, the development of different methods of treatment continues to be a hot research topic. Since its first clinical application at the beginning of the 2010s, abiraterone in the form of prodrug abiraterone acetate continues to be the most used hormon...
Saved in:
Main Authors: | Ivana Z. Kuzminac (Author), Andrea R. Nikolić (Author), Marina P. Savić (Author), Jovana J. Ajduković (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Galeterone for the treatment of advanced prostate cancer: the evidence to date
by: Bastos DA, et al.
Published: (2016) -
Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
by: Rosenberg JE, et al.
Published: (2012) -
Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations
by: Castellan P, et al.
Published: (2018) -
Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer
by: Jean-Marc Ferrero, et al.
Published: (2023) -
Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019)